MTNB

Matinas BioPharma Holdings, Inc. [MTNB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

MTNB Stock Summary

Top 10 Correlated ETFs

MTNB


Top 10 Correlated Stocks

MTNB


In the News

10:44 29 Mar 2024 MTNB

Matinas BioPharma Holdings, Inc. (MTNB) Q3 2023 Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

09:26 29 Mar 2024 MTNB

Penny Stocks To Buy Now? 3 to Watch With Big News

Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.

11:26 29 Mar 2024 MTNB

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Biotech stocks are some of the most volatile in the market because of the regular FDA updates and mergers and acquisitions in the industry. Some of the most notable M&A events this year were Pfizer's acquisition of Seagen, Eli Lilly's buyout of POINT Biopharma and Versanis Bio, and Roche's purchase of Good Therapeutics.

07:00 29 Mar 2024 MTNB

Matinas BioPharma to Present at Two Investment Conferences in October 2023

BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:

07:00 29 Mar 2024 MTNB

Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference

BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

08:00 29 Mar 2024 MTNB

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023

BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report second quarter 2023 financial results after market close on Wednesday, August 9, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

07:30 29 Mar 2024 MTNB

Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023

BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:30 a.m. Eastern time. The conference is being held at the New York Hilton Midtown.

06:59 29 Mar 2024 MTNB

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

07:00 29 Mar 2024 MTNB

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023

BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

06:36 29 Mar 2024 MTNB

7 Small-Cap Biotech Stocks with Massive Potential

While unproven biotechnology firms almost always carry significant risks, small-cap biotech stocks in particular typically impose jaw-dropping volatility. Along with the usual risk of clinical disappointments or outright failures, these speculative enterprises are obviously less funded.

MTNB Financial details

Company Rating
Neutral
Market Cap
60.4M
Income
-17.59M
Revenue
2.16M
Book val./share
0.11
Cash/share
0.08
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
27 Mar 2024
P/E
-2.83
Forward P/E
-2.71
PEG
1.49
P/S
23.01
P/B
2.15
P/C
3.39
P/FCF
-3.26
Quick Ratio
5.64
Current Ratio
6.19
Debt / Equity
0.16
LT Debt / Equity
0.13
-
-
EPS (TTM)
-0.08
EPS next Y
-0.1
EPS next Q
-0.03
EPS this Y
-40%
EPS next Y
23.46%
EPS next 5Y
-75.31%
EPS last 5Y
-15.59%
Revenue last 5Y
92.77%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
7.69%
SMA50
27.27%
SMA100
33.33%
Inst Own
11.36%
Inst Trans
0.96%
ROA
-59%
ROE
-58%
ROC
-0.88%
Gross Margin
-62%
Oper. Margin
-1082%
Profit Margin
-815%
Payout
-
Shs Outstand
217.27M
Shs Float
210.93M
-
-
-
-
Target Price
-
52W Range
0.11-0.89
52W High
-
52W Low
-
RSI
51.66
Rel Volume
1.22
Avg Volume
988.37K
Volume
1.2M
Perf Week
-4.51%
Perf Month
29.05%
Perf Quarter
90.85%
Perf Half Y
92.2%
-
-
-
-
Beta
1.527
-
-
Volatility
0.01%, 0.02%
Prev Close
-6.52%
Price
0.271
Change
-2.17%

MTNB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.01
Net income per share
-0.14-0.11-0.1-0.1-0.06
Operating cash flow per share
-0.11-0.1-0.09-0.07-0.09
Free cash flow per share
-0.11-0.1-0.09-0.07-0.09
Cash per share
0.130.190.30.240.13
Book value per share
0.160.230.320.250.17
Tangible book value per share
0.120.20.30.230.15
Share holders equity per share
0.160.230.320.250.17
Interest debt per share
00.030.020.020
Market cap
58.37M329.59M267.78M212.28M108.41M
Enterprise value
46.32M311.65M259.09M195.95M105.7M
P/E ratio
-4.14-21.15-13-10.03-8.33
Price to sales ratio
487.443.66K1.69K6.37K34
POCF ratio
-5.66-23.39-15.42-13.94-5.66
PFCF ratio
-5.38-22.73-15.41-13.71-5.41
P/B Ratio
3.629.974.24.042.96
PTB ratio
3.629.974.24.042.96
EV to sales
386.773.46K1.64K5.88K33.16
Enterprise value over EBITDA
-3.21-15.64-10.25-7.52-3.76
EV to operating cash flow
-4.49-22.12-14.92-12.87-5.52
EV to free cash flow
-4.27-21.5-14.91-12.66-5.27
Earnings yield
-0.24-0.05-0.08-0.1-0.12
Free cash flow yield
-0.19-0.04-0.06-0.07-0.18
Debt to equity
0.020.130.060.090.11
Debt to assets
0.020.110.050.080.09
Net debt to EBITDA
0.840.90.340.630.1
Current ratio
4.619.6617.2511.738.06
Interest coverage
00006.84
Income quality
0.730.810.770.650.91
Dividend Yield
10.066.782.553.970
Payout ratio
-41.69-143.37-33.15-39.840
Sales general and administrative to revenue
66.6386.463.2305.553.48
Research and developement to revenue
56.68124.8390.69437.55.23
Intangibles to total assets
0.220.110.060.070.1
Capex to operating cash flow
0.050.0300.020.05
Capex to revenue
-4.48-4.51-0.04-7.81-0.28
Capex to depreciation
-2.45-0.52-0.01-0.33-0.99
Stock based compensation to revenue
32.0133.1728.83128.771.64
Graham number
0.730.740.870.750.48
ROIC
-0.85-0.41-0.31-0.36-0.34
Return on tangible assets
-0.9-0.43-0.31-0.37-0.32
Graham Net
0.090.140.260.190.09
Working capital
10.25M26.83M57.99M46.64M30.25M
Tangible asset value
11.79M28.7M59.38M48.14M32.28M
Net current asset value
9.28M22.73M54.32M42.16M26.35M
Invested capital
0.020.130.060.090.11
Average receivables
00000
Average payables
439.26K487.33K514.47K644.11K778.14K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
022.068.9438.2213.53
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
016.5541.030.8326.99
Inventory turnover
00000
ROE
-0.87-0.47-0.32-0.4-0.36
Capex per share
-0.010000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
000.0100
Net income per share
-0.030-0.03-0.03-0.03
Operating cash flow per share
-0.02-0.02-0.02-0.01-0.02
Free cash flow per share
-0.02-0.02-0.02-0.01-0.02
Cash per share
0.150.130.110.10.08
Book value per share
0.180.170.150.130.11
Tangible book value per share
0.160.150.130.110.09
Share holders equity per share
0.180.170.150.130.11
Interest debt per share
0.020.010.020.020.02
Market cap
137.93M108.41M102.11M78.22M28.24M
Enterprise value
130.98M105.7M100.36M72.33M25.55M
P/E ratio
-6.31-832.23-4.69-3.23-1.17
Price to sales ratio
129.81101.9893.1700
POCF ratio
-27.76-25.21-24.99-35.67-6.39
PFCF ratio
-26.43-24.97-24.99-32.66-6.37
P/B Ratio
3.572.963.132.811.22
PTB ratio
3.572.963.132.811.22
EV to sales
123.2899.4491.5700
Enterprise value over EBITDA
-25.04-15.08-18.74-12.21-4.16
EV to operating cash flow
-26.36-24.58-24.56-32.98-5.78
EV to free cash flow
-25.1-24.35-24.56-30.2-5.76
Earnings yield
-0.040-0.05-0.08-0.21
Free cash flow yield
-0.04-0.04-0.04-0.03-0.16
Debt to equity
0.110.110.120.140.16
Debt to assets
0.090.090.10.110.12
Net debt to EBITDA
1.330.390.330.990.44
Current ratio
7.578.0614.889.276.19
Interest coverage
5.53K2.9776.5200
Income quality
0.911.180.740.360.73
Dividend Yield
00000
Payout ratio
0-0.03000
Sales general and administrative to revenue
2.652.522.4700
Research and developement to revenue
3.493.643.6200
Intangibles to total assets
0.090.10.110.130.15
Capex to operating cash flow
0.050.0100.090
Capex to revenue
-0.24-0.04000
Capex to depreciation
-1.08-0.180-0.86-0.07
Stock based compensation to revenue
1.331.261.1600
Graham number
0.320.020.290.280.26
ROIC
-0.120-0.14-0.17-0.19
Return on tangible assets
-0.130-0.16-0.2-0.24
Graham Net
0.110.090.090.080.05
Working capital
32.2M30.25M26.31M21.41M16.76M
Tangible asset value
34.26M32.28M28.27M23.5M18.8M
Net current asset value
28.17M26.35M22.57M17.83M13.35M
Invested capital
0.110.110.120.140.16
Average receivables
00000
Average payables
576.93K637.36K567K560K719.5K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
256.115.93202.79232.31315.76
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.355.650.440.390.29
Inventory turnover
00000
ROE
-0.140-0.17-0.22-0.26
Capex per share
00000

MTNB Frequently Asked Questions

What is Matinas BioPharma Holdings, Inc. stock symbol ?

Matinas BioPharma Holdings, Inc. is a US stock , located in Bedminster of Nj and trading under the symbol MTNB

What is Matinas BioPharma Holdings, Inc. stock quote today ?

Matinas BioPharma Holdings, Inc. stock price is $0.271 today.

Is Matinas BioPharma Holdings, Inc. stock public?

Yes, Matinas BioPharma Holdings, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap